Tumor-associated macrophages (TAMs) are key regulators of the tumor microenvironment, yet the functional specialization of TAM subsets in metastatic progression remains incompletely defined. Here, we characterized distinct TAM populations contributing to tumor-promoting mesothelial cell conversion in high-grade ovarian carcinoma using single-cell RNA sequencing of patient-derived macrophages from ascites (ascTAMs) and omental metastases (omTAMs). TAMs from these anatomical sites were clearly distinguishable by polarization states, with omTAMs exhibiting a mixed M1⁺/M2⁺ phenotype, in contrast to the M1 low /M2⁺ profile observed in ascTAMs. Transcriptomic analysis further revealed functional divergence of these subsets. Notably, omTAMs displayed gene signatures associated with mesothelial-to-mesenchymal transition (MMT), a critical process enabling tumor invasion across the peritoneal lining. Functionally, conditioned media from omTAMs, similar to that from classically activated M1 macrophages, induced MMT in primary mesothelial cells via TGFβ and ERK/p38 MAPK signaling pathways. This phenotypic transition enhanced transmesothelial tumor cell invasion. Proteomic analysis identified IL-1α as a key MMT-inducing factor secreted by pro-inflammatory macrophages. Mechanistically, IL-1α cooperates with TGFβ by activating an autocrine TGFβ/TGFBR1 feedback loop in mesothelial cells, thereby amplifying MMT. Consistent with these findings, IL1A expression was enriched in omTAM clusters across independent patient samples and was confirmed by immunohistochemical analysis of clinical samples. From a therapeutic perspective, our study identifies new avenues to counteract the mesothelial reprogramming driven by IL-1α⁺ TAMs, potentially impeding metastatic progression.
Background: Patients taking multiple medications are at particular risk of cognitive impairment, especially when anticholinergic drugs are involved. Standardised Ginkgo biloba L. leaf extracts (GBE) are a well-established treatment option for cognitive symptoms, but evidence on GBE in combination with concomitant medication remains limited. In this study, we investigated patient-reported outcomes from the pharmacoepidemiologic database PhytoVIS regarding GBE utilization for cognitive impairment in relation to co-medication. Methods: In a study cohort of 191 patients, we examined associations between co-medication and treatment patterns, perceived effectiveness and tolerability of GBE using descriptive statistics and non-parametric bivariate analyses. Anticholinergic burden was assessed using the German Anticholinergic Burden Scale (GABS). Retrospective case reports were prepared for all patients with significant adverse events (SAE) and patients with critical GABS scores. Results: Overall, 64.9% of patients used co-medication, most commonly cardiovascular drugs (47.5%), antidiabetic and analgesics/anti-inflammatory drugs (8.8% each). While there was no association with treatment duration or intake frequency, a higher number of co-medications was linked to lower GBE doses (p=0.03). Three patients reported SAEs during GBE intake, however overall perceived effectiveness and tolerability of GBE remained high irrespective of co-medication. Four GBE users had critical GABS scores (>2); all reported remission of cognitive symptoms. Conclusion: Although more co-medications were associated with lower GBE doses, perceived effectiveness and tolerability remained favourable. However, the findings highlight the importance of monitoring herbal medicinal products in self-medication, particularly in patients with co-medication, while also suggesting that GBE may support the management of cognitive impairment associated with anticholinergic therapies.